CDKN2A and cancer: Fourth, the pre:ada combination causes greater activation of the CDK1 mitotic kinase than either drug used alone and a much greater activation than observed in vehicle-treated cells, suggesting TP53/CDKN2A-deficient cancer cells normally require the combined activity of WEE1 and CHK1 to restrain M-phase entry as part of maintaining genomic integrity.